<DOC>
	<DOCNO>NCT00222183</DOCNO>
	<brief_summary>This trial evaluate therapeutic effect Elidel ( pimecrolimus ) comparison correspond vehicle patient chronic discoid lupus erythematosus ( dLE ) subacute cutaneous lupus erythematosus ( scLE ) .</brief_summary>
	<brief_title>Cutaneous Lupus Erythematosus Elidel</brief_title>
	<detailed_description>Lupus erythematosus autoimmune disease unknown origin classify accord clinical feature , course , laboratory finding . A rough classification divide lupus erythematosus three subgroup : 1. discoid lupus erythematosus ( dLE ) , 2. subacute cutaneous lupus erythematosus ( scLE ) , 3. systemic lupus erythematosus ( sLEsLE ) . The onset lupus erythematosus affect woman three time frequently men , onset 20th 40th year life . It often aggravate triggered multiple factor like UV-light , mainly UV-A , hormone ( thyroid disease ) , pregnancy , oral contraceptive , stress trauma . Some medication might also play role trigger substance , example antibiotic , psychotropic drug , beta blocker , procainamide , diuretic , piroxicam , griseofulvin . The prevalence systemic lupus erythematosus ( sLEsLE ) 12 50/100.000 population worldwide , incidence 2 8/100.000 per year . Skin disease one frequent clinical complaint patient suffer sLEsLE . It find occur 70 % patient course disease . The interesting subgroup LE part study population suffer discoid lupus erythematosus ( dLE ) subacute cutaneous lupus erythematosus ( scLE ) ( Fritsch , 1998 ) . Discoid lupus erythematosus common form chronic form cutaneous LE . It chronic inflammatory disease consist fix , indurate , erythematous papule plaque often distribute head neck . Without intervention , dLE lesion may last many year associate extensive scarring . When dLE occur scalp , permanent scar alopecia may result . If initial work-up patient localize lesion dLE reveal evidence sLEsLE , risk develop sLEsLE low , 5 % . When dLE lesion generalize , risk slightly high . However , dLE lesion uncommon patient establish diagnosis sLEsLE . About 25 % sLEsLE patient develop lesion dLE time course disease ( Fitzpatrick , 1996 ) . Subacute cutaneous lupus erythematosus ( scLE ) first describe late 1970s . These patient suffer cutaneous lesion eruption persistent acute cutaneous lupus erythematosus ( “ butterfly rash ” ) , lasting week month longer . The lesion scLE consist scaly , superficial , inflammatory macule , patch , papule , plaque , photodistributed , particularly upper chest back , lateral neck , dorsal arm forearm . Several different morphologic type scLE described : annular lesion , two type papulosquamous lesion , psoriasiform pityriasiform . About 50 % patient scLE fulfil four criterion classification sLEsLE , though scLE patient experience serious renal CNS involvement lupus erythematosus . Typically , suffer skin disease , photosensitivity , musculoskeletal complaint . Dry eye dry mouth also uncommon . Some patient scLE experience severe manifestation SLEsLE , thus scLE patient monitor systemic disease ( Fitzpatrick , 1996 ) . Frequently , cutaneous complaint concern patient scLE dLE , thus dermatologists generally physician manage disease . Broad spectrum sunscreens sun-protective measure , include lifestyle-changes clothing perhaps important initial measure . Some patient respond potent topical steroid . Oral antimalarial therapy also beneficial many patient . Less commonly use treatment include dapsone , gold , immunosuppressive drug , retinoids , systemic steroid . Standard treatment potent topical corticosteroid effective longtime application provoke atrophy fragility skin well telangiectasias erythema perstans , perioral dermatitis steroid acne . Systemic resorption depend dosage , area , way application result term dysfunction hypothalamus-hypophysis axis describe ( Korting , 1992 ) . Contact allergy uncommon , report ( Lauerma et al . 1993 ) . The main concern skin atrophy follow long-term application topical corticosteroid . Therefore need alternative evident . Pimecrolimus ascomycin macrolactam derivative , act calcineurin inhibitor bind calcineurin ( Dissemond et al , 2002 ) . The consequence calcineurin bind lack activation T helper cell type 1 2 . Further effect compound suggest inflammatory cell , Langerhans cell mast cells/basophils . Both entity , dLE scLE characterize B-cell activation due affect T-cell activation formation multiple autoantibody . This result , among symptom , inflammatory infiltrates , especially face . Pimecrolimus cream already approve treatment atopic dermatitis . Furthermore , study indication like psoriasis , allergic irritant dermatitis . Pimecrolimus develop potential treatment psoriasis , allergic , irritant atopic dermatitis . Animal study tacrolimus ointment cream use lupus dermatoses show promising ( Neckermann et al. , 2000 ; Meingassner et al . 1997 ; Bochelen et al . 1999 ) . Topical tacrolimus therapy apply facial skin lesion 7 case cutaneous lupus erythematosus ( cLE ) . Three systemic LE one discoid show marked regression skin lesion tacrolimus therapy , three patient discoid LE resistant therapy . A good response observe facial erythematosus lesion edematous telangiectatic change systemic LE ( Yoshimasu et al , 2002 , Furukawa et al. , 2002 ) . In discoid LE typical discoid lesion , tacrolimus bring improvement . Pimecrolimus seem promising tacrolimus due alter skin penetration profile . Topical pimecrolimus cream , contrast corticosteroid , provoke skin atrophy ( Dissemond et al. , 2002 ; Queille-Roussel et al . ; 2001 ) might good alternative standard treatment potent corticosteroid , even part patient population respond Elidel® treatment . Topical formulation pimecrolimus cream show effective atopic dermatitis , chronic irritant hand dermatitis , allergic contact dermatitis , also psoriasis , case , semi-occlusive condition . Pharmacokinetic study pimecrolimus cream 1 % indicate consistently low systemic exposure infant , child adult atopic dermatitis regardless extent lesion treat duration therapy . These result support twice daily administration pimecrolimus cream long-term use need basis , limitation duration treatment extent skin surface area treat . The pimecrolimus cream 1 % correspond vehicle devoid significant irritation , contact sensitization , phototoxic , photoallergic potential , standard local tolerability study healthy volunteer . The treatment without occlusion , since occlusive treatment consider clinically relevant area face lupus erythematosus . Untreated lupus plaque patient show equal expression clinical sign erythema , induration scaling . This allow possibility design within-patient study compare various formulation interest efficacy local tolerability . Systemic absorption low . A pharmacokinetic study patient atopic dermatitis apply 1 % pimecrolimus cream twice daily three week show absorption 72 % case . Side effect observe ( van Leent et al. , 1998 b ) . In view biological profile , clinical hypothesis formulate claim Elidel® well tolerate effective treatment cutaneous lupus erythematosus ( scLE dLE ) . This study design test hypothesis .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subjects may include fulfil follow inclusion criterion pretreatment day ( Day 14 Day 2 ) Day 1 ( first application study medication ) : 1 . Female male patient age 1865 year ( female childbearing potential may enrol provide routinely use adequate contraception assessment investigator ) . 2 . Patients histologically define dLE scLE . 3 . The test site ( lupus erythematosus plaque ) must face , total sign score 4 ( sum erythema , induration scaling score ) must within give patient ( ie differ sum erythema , induration scaling ) . Each 2 test site must least 3 cm apart . 4 . The patient must receive baseline medication chloroquine . 5 . Patients must inform study procedure medication must give write Informed Consent . 6 . Patients expect available duration study able comply study visit . Any following criterion disqualify patient participate study : 1 . Systemic therapy lupus erythematosus within one month prior first application study medication study ( steroid , retinoids , herbal medicine , etc ) except chloroquine . 2 . Patients systemic lupus erythematosus patient whose chronic discoid lupus erythematosus appear spontaneously flare improve base experience investigator . 3 . Patients receive oral medication , know precipitate lupus lesion ( e.g . procainamide , diuretic , piroxicam , beta blocker , griseofulvin , lithium psychotropic drug ) . 4 . Topical therapy [ i.e . corticosteroid , etc . ] within 2 week prior first application study medication . 5 . Patients clinically significant medical condition could interfere conduct study . This include : Renal impairment ( creatinine &gt; 2.0 mg/dl ) Hepatic impairment ( liver function test value notable abnormality ; gGT , ALAT , ASAT : 2x upper limit ) Haematologic disorder ( haemoglobin , platelet , erythrocyte leukocyte count notable abnormality ) Neurologic disorder ( significant impairment sensory motor function judge investigator ) Patients know previously immunocompromised ( e.g . lymphoma , AIDS , myelodysplastic disorder ) treat recently immunosuppressive drug treatment ( e.g . radiation therapy chemotherapy ) . HIV test necessary . Patients clinically relevant cardiovascular disease ( New York Heart Association [ NYHA ] III IV ) 6 . Patients suffer systemic generalized infection ( bacterial , fungal , viral ) 7 . Patients malignancy history malignancy . 8 . Patients suffer acute chronic bacterial , viral , fungal skin disease . However , patient tinea pedum and/or onychomycosis include . Likewise , patient acute herpes lesion exclude . 9 . Patients history drug alcohol abuse past 1 year . 10 . Patients know hypersensitivity ingredient study medication tacrolimus ( investigator provide list ingredient study medication ) . 11 . Patients receive investigational drug within 4 week prior first application study medication . 12 . Patients unwilling unable provide Informed Consent participate satisfactorily entire trial period . 13 . Any condition , opinion investigator , would render patient ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Lupus erythematodes</keyword>
	<keyword>Elidel</keyword>
	<keyword>Pimecrolimus</keyword>
	<keyword>Chronic discoid lupus erythematosus ( dLE )</keyword>
	<keyword>subacute cutaneous lupus erythematosus ( scLE )</keyword>
</DOC>